Gelonghui, May 11 | Huadong Pharmaceutical (000963.SZ) said on the interactive platform that the company's simeglutide injection project is progressing according to plan. All subjects of the Phase III clinical study on diabetes indications have now been enrolled, and it is expected that the main endpoint data will be obtained in Q4 2024.
华东医药(000963.SZ)：糖尿病适应症目前已完成III期临床研究全部受试者入组，预计2024年Q4获得主要终点数据
Huadong Pharmaceutical (000963.SZ): Diabetes Indications have now completed the Phase III clinical study and all subjects have been enrolled. It is expected that the main endpoint data will be obtained in Q4 2024
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.